Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$22.0 million.

  • Silence Therapeutics' Cash from Investing Activities rose 234.48% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.0 million, marking a year-over-year increase of 55.34%. This contributed to the annual value of -$22.0 million for FY2024, which is 213.85% down from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Cash from Investing Activities is -$22.0 million, which was down 213.85% from $19.3 million recorded in FY2023.
  • Silence Therapeutics' 5-year Cash from Investing Activities high stood at $19.3 million for FY2023, and its period low was -$22.0 million during FY2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$20.5 million (2022), whereas its average is -$7.7 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 271.72% in 2022, then surged by 194.13% in 2023.
  • MRY analysis of 5 years shows Silence Therapeutics' Cash from Investing Activities stood at $12.4 million in 2020, then dropped by 3.35% to $11.9 million in 2021, then tumbled by 271.72% to -$20.5 million in 2022, then skyrocketed by 194.13% to $19.3 million in 2023, then tumbled by 213.85% to -$22.0 million in 2024.
  • Its Cash from Investing Activities stands at -$22.0 million for FY2024, versus $19.3 million for FY2023 and -$20.5 million for FY2022.